Self-Measurement of Blood Glucose in Patients with Type 2 Diabetes: A Health Economic Assessment

C. Weber,K. Neeser,B. Schneider,V. Lodwig
DOI: https://doi.org/10.1177/193229680700100511
2007-09-01
Journal of Diabetes Science and Technology
Abstract:Background: The clinical role and the potential benefit of self-measurement of blood glucose (SMBG) for patients with type 2 diabetes are still under discussion. Even less information is available on the cost-effectiveness of performing SMBG by this patient group. The goal of this study was to establish cost-effectiveness ratios of performing SMBG by patients afflicted by this disease. Methods: We assessed the benefit and cost-effectiveness of SMBG in type 2 diabetes from a third-party payer perspective based on results of both a large epidemiologic cohort study reflecting the reality of care, and a Markov model calculation. Results: Analysis of cohort study data revealed that total costs cumulated over the observation period of 8 years were lower in the SMBG group than in the non-SMBG group according to savings of € 1'714 [oral antidiabetic drugs (OAD) only] and € 13'815 (OAD + insulin) per patient. Several scenarios were considered in the model-based calculation. The cost-effectiveness ratio varied from € 20'768/life year gained to domination of SMBG use compared to nonusers in OAD treated patients and from € 59'057/life year gained to domination of SMBG use compared to nonusers in OAD + insulin treated patients. Conclusion: Results indicate that SMBG in type 2 diabetes offers an excellent opportunity to get a high investment-outcome ratio in the treatment of this pandemic disease.
What problem does this paper attempt to address?